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Recent guidelines in British Columbia, Canada have suggested that the use of a maximum of 3 monthly
doses of palivizumab 15mg/kg intramuscularly for RSV immunoprophylaxis of high risk infants born prior
to the RSV season is adequate to provide protection against severe RSV disease for a 5-month RSV season.
Efﬁcacy was established, however, with 2 large, randomized controlled clinical studies using 5 monthly
doses of immunoprophylaxis. To evaluate the differences in expected palivizumab exposures between the
2 dosing regimens (3 vs 5monthly doses across a 5-month period), we used a population pharmacokinetic
(PK) model that was developed using palivizumab PK data collected from 22 clinical studies with a total of
1800 subjects. This model adequately described observed palivizumab concentrations from the different
pediatric studies andwas subsequently used to simulate expected palivizumab serum concentrations for 3
monthly doses compared with 5 monthly doses in children younger than 24 months with chronic lung
disease of prematurity and infants younger than 6 months postnatal age who were born at 35 weeks
gestational age. Results from the population PK model indicated lower serum concentrations of pal-
ivizumab during the fourth and ﬁfth months, after an abbreviated 3-monthlyedose regimen when
compared with the mean trough concentrations seen with the 5-monthlyedose regimen studied in the
pivotal clinical trials in premature infants. Speciﬁcally, during the fourth and ﬁfth months, 52% and 85%,
respectively, would have levels below the lowest concentration (ﬁfth percentile) in those receiving the
5-monthly-dose regimen. Simulations using this model did not support a 3-monthlyedose regimen to
protect against severe RSV disease during the typical 5-month season.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
RSV is ubiquitous and immunity is not durable after natural
infection, which makes prevention of transmission and subsequent
infection a challenge [1e3]. Even in the hospital setting with
attention to infection control, it is difﬁcult to completely prevent
transmission [1]; in the community and household setting, it is
virtually impossible. Therefore, RSV remains one of the mostaithersburg, MD 20878, USA.
lp@gmail.com (W.V. La Via),
edimmune.com (X.-Q. Yu),
r.noertersheuser@abbott.com
. Robbie).
-NC-ND license.important causes of hospitalization in infants [4] and the incidence
of RSV hospitalizations in young infants has remained consistently
high over the past decade [5,6]. Populations at highest risk include
infants who are born prematurely (35 weeks gestational age
[wGA]) with or without chronic lung disease of prematurity
(CLDP; formerly known as bronchopulmonary dysplasia [BPD]), or
who have hemodynamically signiﬁcant congenital heart disease
(CHD) [6].
Lack of a safe and effective RSV vaccine supported development
of palivizumab and its subsequent licensing in the US in 1998 and in
the European Union in 1999. Palivizumab binds a conserved anti-
genic site on the fusion (F) protein of RSV and prevents the fusion of
infected cells, which reduces viral activity and cell-to-cell trans-
mission of the virus, thereby decreasing the incidence of severe
lower respiratory tract infection [7]. Palivizumab is now approved
W.V. La Via et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 666e671 667in approximately 80 countries for the prevention of serious lower
respiratory tract disease caused by RSV in pediatric patients at high
risk for severe RSV disease [8].
Palivizumab only confers passive immunity; therefore, protec-
tion against RSV depends on augmenting and sustaining pal-
ivizumab levels for the duration of exposure to RSV. In temperate
areas of the United States, the RSV season has a median duration of
20 weeks, which varies annually by geographic location [9,10]. The
epidemiologic patterns of RSV may be similar for many other
temperate regions around the globe. However, the length of RSV1000
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Fig. 1. Palivizumab serum concentrations for the 5-monthlyedosing regimen. A, Actual IMp
palivizumab. Palivizumab dosing was 15 mg/kg IM. The blue line indicates the median conce
an observed concentration. B, A representative panel of 16 individual patients from the p
breviations: IM (intramuscular), RSV (respiratory syncytial virus).seasons varies in some parts of the world depending on climate or
other cultural or demographic factors (eg, age or crowding) [11e18].
In some regions, RSV activity is prevalent year-round [18e20].
Preclinical studies in a cotton rat model and clinical pharma-
cokinetic studies were used in the selection of a regimen of
monthly doses given at 15 mg/kg during the RSV season [21]. In the
cotton rat model, serum levels of 40 mg/mL led to a 99% (2 log) viral
titer reduction in all animals [7,22]. This monthly regimen was
successful at decreasing RSV hospitalization in high-risk infants
and children and ultimately led to the licensure of palivizumab90 120 150
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Table 1
IMpact-RSV study serum trough concentrations after palivizumab 15 mg/kg IM
monthly in infants.
Injection
numbera
n Mean  SD Palivizumab
trough levels, mg/mL
1 328 37  21
2 300 57  41
3 297 68  51
4 892 72  50
Abbreviations: IM (intramuscular), RSV (respiratory syncytial virus).
a Samples were taken 30 days after each injection.
W.V. La Via et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 666e671668[8,21]. The common adverse effects of palivizumab seen in that
study include fever, cold-like symptoms (upper respiratory tract
infection), including runny nose and ear infection, and rash.
Since then, global registry data has conﬁrmed the effectiveness
of palivizumab in widespread clinical use. In the US, 4 years of
registry data, comprising 19,548 patients, demonstrated a hospi-
talization rate of 1.3% in treated high-risk infants [23]. Similarly, the
palivizumab Special Access Programme of Canada’s Therapeutic
Products Programme, revealed hospitalization rates of 2.4% [24]. In
the German Palivizumab Registry, the hospitalization rate related
to RSV was 2.5% [25]. Non-compliance with the monthly dosing
interval has been associatedwith increased RSV hospitalization risk
[23]. Recent guidelines in British Columbia, Canada recommend
deviation from the regimen of monthly doses of palivizumab over
the RSV season based on the half-life of palivizumab [26]. The
primary justiﬁcation for this recommendation is cost containment;
however, recently published cost-utility studies conﬁrmed the
cost-effectiveness of full-season dosing in the US [27,28] and in
several other countries [29e31]. To evaluate the effect of abbrevi-
ated dosing on palivizumab serum concentrations, clinical PK data
were modeled and scenarios for 3 vs 5 monthly doses during a 5-
month period were simulated [32]. We also present for the ﬁrst
time detailed PK data from the randomized clinical trial of pal-
ivizumab that established efﬁcacy in high-risk premature infants.1000
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Fig. 2. Simulated palivizumab serum concentrations. A, Children <24 months postnatal a
Abbreviations: CLD (chronic lung disease of prematurity), wGA (weeks gestational age). Red
shading indicates the 5th and 95th percentiles for the 3-monthlyedose regimen.2. Methods
The pharmacokinetics of palivizumab in pediatric and adult
populations was adequately described by a 2-compartment model,
and details of the population PK model development have been
described previously [32]. The model-predicted 5the95th percen-
tile band described 84.8%, 90.8%, 90.7%, and 90.7% of observed
trough concentrations after the 1st, 2nd, 3rd, and 4th doses,
respectively from the IMpact trial (MI-CP018), supporting the ad-
equacy of the model (Fig. 1). Based on the population PK model
[32], two dosing regimens (3 monthly doses of 15 mg/kg and 5
monthly doses of 15 mg/kg) were simulated using Pharsight Clin-
ical Trial Simulator (Version 2.2.1) with Visual Fortran Compiler
(Pharsight Corporation, Mountain View, CA). For the simulations,
the distributions of covariates for the full population of high-risk
children were assumed to be the same as in the IMpact-RSV trial
with respect to body weight, gestational age (GA), postnatal age
(PA) at start of the study, and presence of antipalivizumab anti-
bodies. The clinical trial simulation included 2000 total subjects
divided into 2 treatment arms, 3 monthly doses and 5 monthly
doses. Total (100%) compliance was assumed (ie, all subjects were
simulated to receive the appropriate number of doses (3 or 5) with
30 days between each dose). Additional simulations were con-
ducted to predict serum concentrations for the subpopulations of
children younger than 24months with CLD and in infants35wGA
younger than 6 months.
3. Results
The population PK model accurately described the median
concentration and associated variability of the observed data
(Table 1, Fig. 1A). The PK proﬁle established by the model is
consistent with the label-reported half-life of 20 days for pal-
ivizumab. With 5 monthly doses, median serum palivizumab con-
centrations increased with each dose and reached steady state by1000
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dosing (Figs. 2e4). Subpopulations (children younger than 24
months with CLD and infants younger than 6 months who were
born at 35 wGA) exhibited PK proﬁles similar to the full popula-
tion of high-risk children (Fig. 2). In addition, minimal differences
in PK proﬁles were predicted between the 2 subpopulations (Figs. 2
and 3). After 3monthly doses, serum palivizumab concentrations in
52% and 85% of the subject population in the fourth and ﬁfth
months, respectively, would be below the ﬁfth percentile concen-
trations seen in the population who received 5 monthly doses in
the clinical trial [8].
With 5 monthly doses of 15 mg/kg, the model predicts that only
approximately 24% of patients would have trough levels<40 mg/mL
onemonth after the third dose. This is consistent with the observed
median trough levels from the IMpact-RSV trial (Fig. 4) which
increased from 35.5 mg/mL after the ﬁrst dose to 62.9 mg/mL after
the third dose. Thereafter, median trough concentrations remained
the samewith a value of 64.4 mg/mL after the fourth dose, indicating
achievement of steady state. The reported values from the IMpact
study (Fig. 4) demonstrated substantial inter-individual variability
in serum levels; the 5the95th percentile values for the third and
fourth dose trough levels ranged from 19.6 mg/mL to 126.7 mg/mL,
and 19.9 mg/mL to 149.9 mg/mL, respectively. Intra-individual vari-
ability in trough concentrations was also observed in the IMpact-
RSV trial (Fig. 1B). These data demonstrate that this phenomenon
affects a substantial proportion of infants. Examining the trough0 30 60 90 120 150
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Fig. 3. Simulated palivizumab serum concentrations. A, For the 3-monthlyedose
regimen. B, For the 5-monthlyedose regimen. Abbreviations: CLD (chronic lung dis-
ease of prematurity), PA (postnatal age), wGA (weeks gestational age).levels before doses 4 and 5 d as depicted in Fig. 4 d reveals that
nearly the entire bottom quartile are below the preclinical target.
Replenishing serum concentrations with a subsequent dose would
provide ongoing protection if RSV were still circulating.
With abbreviated 3-monthly doses, the model predicts that the
majority of patients will have concentrations below 40 mg/mL by
the end of the fourth month [7]. By the end of the ﬁfth month, 96%
of the patients will have concentrations below 40 mg/mL (Fig. 2C).
4. Discussion
The population PK model adequately described the PK of pal-
ivizumab in children with prematurity or CLD based on data from
the phase 3 IMpact-RSV study [21]. Based on comparisons of
simulated data and actual observations, the NONMEM population
PK model predicted palivizumab trough concentrations similar to
those measured in that phase 3 clinical trial [32]. This analysis
supports the use of the validated model to evaluate palivizumab PK
using clinical trial simulations. The model predicted that a majority
of children at risk for serious lower respiratory tract disease caused
by RSV who receive 3 monthly doses of palivizumab 15 mg/kg IM
would have lower palivizumab concentrations in months 4 and 5
compared with children receiving 5 monthly doses. In clinical
studies, 5 monthly doses of palivizumab 15 mg/kg administered IM
was associated with a 55% reduction in hospitalizations caused by
RSV in high-risk children, more than 90% of whom received all 5
doses [21,33].
Monthly dosing was chosen based on the average half-life of the
IgG antibody and with a goal toward reducing the proportion of
patients with subtherapeutic serum concentrations. Other antiviral
agents are commonly used in a therapeutic setting enabling one to
monitor and evaluate the effect of different concentrations of drug
on viral titer reduction. In contrast, palivizumab is used prophy-
lactically in the absence of measurable viral titers making it chal-
lenging to identify a protective serum level of palivizumab that
would result in viral titer reduction or prevent hospitalization in
the clinic. Furthermore, like all monoclonal antibodies, palivizumab
levels change with time, making it difﬁcult to identify a precise
palivizumab level that is associated with a reduction in RSV hos-
pitalization risk. For the above reasons, a protective level of pal-
ivizumab in humans has not been established. Presently, the most
reliable data available are from the randomized controlled trials
that demonstrated protection with 15 mg/kg monthly dosing of
palivizumab throughout the RSV season. Given the RSV hospitali-
zation rate, clinical studies to evaluate different dosing regimens
would be prohibitively large, logistically unfeasible, and potentially
unethical because effective therapy has been established with
15 mg/kg monthly dosing of palivizumab throughout the RSV
season. An example of a clinical trial failure that may have been
caused by inadequate dosing is that of another MAb directed
against the RSV F protein, SB 209763. This MAb, although effective
in the animal model, failed to prevent RSV hospitalization at a dose
of 10mg/kg (a dose lower than that recommended for palivizumab)
in a phase 3 clinical study of high-risk infants [34]. This highlights
that a threshold level of MAb might be needed for successful pro-
phylaxis and the challenge of translating preclinical target levels in
animals into successful clinical trials in humans.
The population PK behavior of palivizumab also exhibits sub-
stantial interpatient variability (ﬁrst observed in serum concen-
trations from the IMpact-RSV trial) [8]. The population PK model
indicated that none of the covariates could account for this inter-
patient variability in serum levels [32]. In the clinical trials, there
are some individuals with persistently low concentrations, with no
increase upon multiple dosing, or some who have lower concen-
trations at later time points compared with earlier time points.
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W.V. La Via et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 666e671670Premature termination of dosing in these individuals would place
them at risk of RSV disease while the RSV season is ongoing. The
current analysis also indicates that in the small number of patients
who have palivizumab concentrations much higher than median
values before termination of dosing after 3 months, protection from
RSV might still be maintained. However, these patients cannot be
identiﬁed in advance of the decision to discontinue prophylaxis due
to the lack of predictors identifying patients with low or high
concentrations of palivizumab. Without the availability of antibody
serum concentration monitoring (or the knowledge of the mini-
mum protective level in humans), it is not possible for a clinician to
predict which patients will be vulnerable to hospitalization from
RSV infection. As a result, the use of monthly dosing throughout the
season remains the appropriate dosing regimen for high-risk in-
fants. Limiting patients to insufﬁcient dosing of palivizumab may
put them at risk for severe RSV disease. With recent improvementsin the availability of RSV epidemiologic data, local virology data is
the optimal way to deﬁne the length of any given RSV season [10].
Limitations of this analysis are that no data exist that relate
palivizumab serum concentrations at time of hospitalization with
breakthrough RSV infection leading to hospitalization, and rates of
RSV infection in children with serum levels lower than those ob-
tained in the phase 3 clinical trial are not available to clinically
validate the risk presented by this PK simulation model. The model
(and resulting simulations) may not adequately describe all groups
at high risk for serious RSV disease, such as those with CHD.
5. Conclusions
Simulations using this PK model did not support a 3-monthlye
dose palivizumab regimen to protect against severe RSV disease
over a 5e6 month RSV season. The regimen of monthly doses of
W.V. La Via et al. / Pulmonary Pharmacology & Therapeutics 26 (2013) 666e671 671palivizumab throughout the season has been established as efﬁ-
cacious in clinical trials, supported by approved labeling, and used
in clinical practice for more than a decade.
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